The potent and synergistic mitogenic activity of FLT3 ligand (FL), c-kit ligand (Stem Cell Factor, SCF) and c-Thrombopoietin (TPO) on cord blood hematopoietic progenitors and primitive stem cells has been previously demonstrated. Thus we chose to focus on these cytokines without or with the addiction of IL6 and IL3, to investigate their effect on the proliferation, the self renewal potentials and the in vivo repopulating capability of CD34+ cells of different ontological status (bone marrow, BM and mobilized peripheral blood, MPB) after ex vivo expansion. CD34+ cells were cultured in stroma-free suspension cultures in IMDM containing either 10% FCS or pooled human serum in the presence of various combinations of FL,SCF,TPO,IL6±IL6R and IL3. Cultures were either demi-depopulated every week by removal of half culture volume, which was replaced by the same amount of fresh medium and growth factors either doubled every week by adding the same volume of fresh medium and growth factors. Cells of each set of wells were harvested weekly, counted and aliquots were kept for assessment of immunophenotype,CFC and LTC-IC content. Of the various growth factor (GF) combinations many proved able to sustain a certain degree of cell production, which, after 6-7 weeks, ranged from 4.8 x 106 to 268 x 106 cells/well. When suspension cultures were extended for longer periods of time, only a few GF combinations, conaining FL,SCF,TPO±IL6 proved capable of supporting a prolonged and increasingly greater cells production, which persisted for up to 16 weeks and reached 125,000-fold the initial number. Accordingly, also the output of committed progenitors persisted and kept increasing up to 12-15 weeks (up to Ͼ 7,000-fold). Limiting Dilution Analyses showed that not only LTC-IC persisted, but also underwent a certain degree of expansion (up to 5 weeks). To demonstrate that the expanded cells also retained their in vivo repopulating ability, sublethally irradiated NOD/SCID mice were injected with either decreasing concentrations of unmanipulated CD34+ BM and MPB cells either the corresponding progeny of initial 40 to 80x103CD34+ cells which were expanded in vitro for up to 3weeks. BM cells Cytofluorimetric and DNA analysis of the engrafted animals showed that SRC were not only maintained up to 25 days of cultures, but also expanded after 2 to 3 weeks. However, in contrast to CB experiments, FL+TPO were necessary, but not sufficient to allow such an expansion. In addition to these two growth factors, other growth factors, among which SCF, IL6; IL6+IL6R and also very low doses of IL3 seem to be important for SRC maintenance and expansion of BM and MPB more primitive stem cells.
M. Aglietta, L. Gammaitoni, S. Bruno, M. Gunetti, F. Sanavio, F. Fagioli, W. Piacibello (Torino, I) The potent and synergistic mitogenic activity of FLT3 ligand (FL), c-kit ligand (Stem Cell Factor, SCF) and c-Thrombopoietin (TPO) on cord blood hematopoietic progenitors and primitive stem cells has been previously demonstrated. Thus we chose to focus on these cytokines without or with the addiction of IL6 and IL3, to investigate their effect on the proliferation, the self renewal potentials and the in vivo repopulating capability of CD34+ cells of different ontological status (bone marrow, BM and mobilized peripheral blood, MPB) after ex vivo expansion. CD34+ cells were cultured in stroma-free suspension cultures in IMDM containing either 10% FCS or pooled human serum in the presence of various combinations of FL,SCF,TPO,IL6±IL6R and IL3. Cultures were either demi-depopulated every week by removal of half culture volume, which was replaced by the same amount of fresh medium and growth factors either doubled every week by adding the same volume of fresh medium and growth factors. Cells of each set of wells were harvested weekly, counted and aliquots were kept for assessment of immunophenotype,CFC and LTC-IC content. Of the various growth factor (GF) combinations many proved able to sustain a certain degree of cell production, which, after 6-7 weeks, ranged from 4.8 x 106 to 268 x 106 cells/well. When suspension cultures were extended for longer periods of time, only a few GF combinations, conaining FL,SCF,TPO±IL6 proved capable of supporting a prolonged and increasingly greater cells production, which persisted for up to 16 weeks and reached 125,000-fold the initial number. Accordingly, also the output of committed progenitors persisted and kept increasing up to 12-15 weeks (up to Ͼ 7,000-fold). Limiting Dilution Analyses showed that not only LTC-IC persisted, but also underwent a certain degree of expansion (up to 5 weeks). To demonstrate that the expanded cells also retained their in vivo repopulating ability, sublethally irradiated NOD/SCID mice were injected with either decreasing concentrations of unmanipulated CD34+ BM and MPB cells either the corresponding progeny of initial 40 to 80x103CD34+ cells which were expanded in vitro for up to 3weeks. BM cells Cytofluorimetric and DNA analysis of the engrafted animals showed that SRC were not only maintained up to 25 days of cultures, but also expanded after 2 to 3 weeks. However, in contrast to CB experiments, FL+TPO were necessary, but not sufficient to allow such an expansion. In addition to these two growth factors, other growth factors, among which SCF, IL6; IL6+IL6R and also very low doses of IL3 seem to be important for SRC maintenance and expansion of BM and MPB more primitive stem cells. Recently we demonstrated that the CAFC numbers in the bone marrow of patients after allogeneic transplantation in early leukaemia stages (AML 1st CR, CML 1st chronic phase) are significantly higher (156 CAFC-d35 per 10e6 low density bone marrow cells (LDBMC), range 59 to 305) when compared to patients transplanted in more advanced leukaemia stages (72 CAFCd35 per 10e6 LDBMC, range 46 to 138). Here we extend these findings to cases of myelodysplastic syndrome which show significantly lower CAFC numbers (69 CAFC-d35 per 10e6 LDBMC, range 45 to 86) after allogeneic transplantation as compared to early stage leukemia. Compared to normal bone marrow (704 CAFC-d35 per 10e6 LDBMC, range 453 to 1024) numbers of CAFC as a measure for immature haemopoietic cells are reduced in patients after allogeneic PBSCT (104 CAFC-d35 per 10e6 LDBMC, range 45 to 305) as has been shown for patients after allogeneic BMT (116 CAFC-d35 per 10e6 LDBMC, range 38 to 257). No correlations of CAFC numbers were found with 1) the age of the patients, 2) interval after transplantation, 3) sex of the patients, 4) stem cell dose or 5) stem cell source (BM versus PBSC). Because of the latter finding our data indicate that PBSC do not have an increased capacity to repopulate the early stem cell compartment as compared to BM cells. Significant correlations (p-value Ͻ 0.05) of CAFC numbers with stage of disease or disease type were found (early versus advanced leukemia p Ͻ 0,016, early stage leukemia versus MDS p Ͻ 0,034, early versus advanced leukemia including MDS p Ͻ 0,002). No significant difference between advanced leukemia and MDS p = 0,88 was found. The lowest CAFC numbers were found in a case of retransplantation for acute lymphoblastic leukaemia (22 CAFC-d35 per 10e6 LDBMC). CFU-GM numbers were comparable in all groups and did not differ from normal bone marrow controls. In conclusion we could show that the pretransplantation state of the patient bone marrow as defined by the type and stage of the underlying leukemia rather than the transplantation procedure itself has significant influence on the engraftment of early haemopoietic stem cells as defined by CAFC numbers.
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Functional characterization of AC133+ peripheral blood stem cells L. Forte, T. Caravita, S. Santinelli, A. Siniscalchi, S. Di Cesare*, L. Maurillo, G. Adorno, G. Ballatore, A. Bruno, P. Rossi*, S. Amadori (Rome, I) Introduction: The AC133 antigen seems to identify better than the CD34 antigen most primitive hematopoietic stem cell (Miraglia S, 1997; Gehling, 2000; DeWinter, 1998) and may play an important role in stem cell selection for transplantation and ex vivo expansion of progenitors. We analyzed the clonogenic activity and the ex vivo expansion ability of the AC133+ fraction obtained from CD34+ peripheral blood stem cells (PBSC) immunoselected by CliniMacs (Milteny) from normal donors. Materials and Methods: AC133+ cells were selected from CD34+ PBSC (purity = 96±4 %) using MiniMACS columns (Milteny Biotec). Hematopoietic primitive progenitor-quiescent (HPP-Q) cells were evaluated seeding AC133+ cells in semisolid medium in presence of antisense Transforming Growth Factor-beta1 (TGF-beta1). The antisense TGF-beta1 is able to activate HPP-Q which normally could not grow in short term semisolid assay (HPP-Q assay StemBio Research, Villejuif). Furthermore, CFU-GM, BFU-E and CFU-GEMM were tested in semisolid medium (Methocult H4434 Stem Cell Technologies). Moreover two weeks serum free liquid culture (Stemspan, Stem Cell Tecnologies) of both total CD34+ cells and AC133+ fraction were established with SCF (10 ng/mL), IL-3 (10 ng/mL) and OSM (10 ng/mL); the proliferative response was assessed at day 7 and day 14 by evaluating the following parameters: number of cells, viability, clonogenic ability and immunophenotype (CD34, AC133, CD3, CD19, CD14, CD11b, CD11c). Results: In the AC133+ fraction the numbers of HPP-Q, CFU-GM and CFU-GEMM are increased respect to the AC133-fraction (Table1). During the 2-week serum free liquid culture both CD34+ and AC133+ cells displayed an increased ability of giving rise to committed progenitors, although the AC133+ fraction showed a 5.5±1.9 fold higher expansion of CFC colonies, a 4.8 ± 0.4 fold higher expansion of CFU-GM colonies and a 3.3± 2 fold higher expansion of CFU-GEMM colonies (pϽ 0.01). Furthermore, flow cytometry analysis showed in the AC133+ fraction an increasing expression of CD14, CD11b, CD11c and in particular of CD11b (pϽ0.001). Conclusions: The data suggest that the AC133+ PBSC fraction contains both of immature stem cell, that can be activated from anti TGF-beta1, and more differentiated hematopoietic progenitor cells; moreover these cells can be maintained and expanded in defined culture conditions.
OS297
Memory B lymphocytes determine repertoire oligoclonality after hematopoietic stem cell transplantation B. Omazic, I. Nä sman Bjö rk, J. Mattsson, J. Permert, I. Lundkvist (Stockholm, S)
Reconstitution of the immune system after hematopoietic stem cell transplantation (HSCT) is dependent on the conditioning regimen, the effect and treatment of graft-versus-host disease (GVHD) and time after HSCT. Components of the non-specific immune system recover within 2-6 months, whereas functional recovery of B and T lymphocytes may take more than 1 year. The most variable region of the antigen binding part of the antibody molecule is the third complementarity determining region (CDR3). Analysing the total B lymphocyte population, including naive as well as activated B lymphocytes, we have previously demonstrated clonal dominance by different CDR3 regions at different time points after HSCT. The aim of this study was to investigate if oligoclonality of the Ig repertoire is restricted to memory B lymphocytes or if it is an common property of all B lymphocytes. We have studied the size distribution of the IgH CDR3 region in naive and memory B lymphocytes isolated from patients undergoing HSCT. Samples from 10 patients were collected before HSCT and at 3, 6 and 12 months post HSCT. Memory and naive populations of B lymphocytes were separated with immunomagnetic beads coupled with antibodies against CD19, a general B lymphocyte surface marker, and CD27, a surface marker for memory B lymphocytes. The CDR3 region was amplified with PCR, separated on a polyacrylamid gel and analysed using the software GeneScanä . We demonstrate a limited variation of the IgH CDR3 repertoire in the memory B lymphocyte population compared to the naive B cell population. This difference was significant at 3 and 6 months post HSCT. At 3 months post HSCT there is also a significant restriction of the total B lymphocyte repertoire due to the oligoclonality of the memory B lymphocytes. Thus, our findings suggest a memory cell specific restriction of the oligoclonal B cell repertoire observed early after HSCT. A restricted B lymphocyte repertoire probably results in limited immune reactivity and poor immune responses to bacterial infections in patients early after HSCT.
